Data_Sheet_1_Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice.docx
Background: Patient involvement is often acknowledged as an important aspect of the lifecycle of medicines. Although different typologies exist, patient involvement has been described as the involvement of patients in decision-making regarding medicines. In view of the diversity of stakeholders and types of decisions in which patients might be involved, an in-depth understanding of these stakeholders' views toward involving patients in the lifecycle of medicines is essential. Methods: Interviews and surveys were used to gain insights into the perspectives and experiences of Belgian healthcare... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Dataset |
Erscheinungsdatum: | 2018 |
Schlagwörter: | Dermatology / Emergency Medicine / Gastroenterology and Hepatology / Geriatrics and Gerontology / Intensive Care / Medical Genetics (excl. Cancer Genetics) / Nephrology and Urology / Nuclear Medicine / Orthopaedics / Otorhinolaryngology / Pathology (excl. Oral Pathology) / Radiology and Organ Imaging / Foetal Development and Medicine / Obstetrics and Gynaecology / Family Care / Primary Health Care / Medical and Health Sciences not elsewhere classified / patient involvement / decision-making / lifecycle of medicines / patient preferences / evaluation of medicines / reimbursement / medicines development / market access |
Sprache: | unknown |
Permalink: | https://search.fid-benelux.de/Record/base-27311698 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.3389/fmed.2018.00285.s001 |
Background: Patient involvement is often acknowledged as an important aspect of the lifecycle of medicines. Although different typologies exist, patient involvement has been described as the involvement of patients in decision-making regarding medicines. In view of the diversity of stakeholders and types of decisions in which patients might be involved, an in-depth understanding of these stakeholders' views toward involving patients in the lifecycle of medicines is essential. Methods: Interviews and surveys were used to gain insights into the perspectives and experiences of Belgian healthcare stakeholders. Interviews (n = 22) were conducted with academics, hospital pharmacists and representatives from health insurance funds, the Belgian reimbursement agency, pharmaceutical industry and patient organizations. Interviews underwent a framework analysis. Surveys (n = 108) were completed by hospital visitors and analyzed descriptively. Results: Despite an increasing amount of efforts to involve patients, interviewees labeled the level of actively involving patients as rather low and scattered across the different phases of the lifecycle of medicines. The main opportunities for patient involvement highlighted by interviewees were for: (i) informing early development decisions on which treatments to develop, (ii) clinical trial endpoint selection and (iii) clinical trial protocol design. However, remaining questions surrounding patient knowledge, and particularly how and which patients to involve represent important barriers toward implementing patient involvement in the lifecycle of medicines. Of survey participants, 77% indicated to be willing to participate in patient preference studies. Reasons for participating mentioned most frequently were “to improve development of treatments,” because “it is important to explore and listen to patient preferences” and “to have a voice as patients”. Conclusions: The barriers identified in this study hamper transitioning patient involvement from theory to practice. Bridging this ...